Related Experiment Video

Updated: Jun 1, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.2K

Recent advances in therapeutic strategies of Erdheim-Chester disease

Rohit Doke1, Rahul Lokhande2, Kalyani Chande3

  • 1Jaihind College of Pharmacy, Vadgaon Sahani, Pune, Maharashtra, 412401, India.

Naunyn-Schmiedeberg'S Archives of Pharmacology
|January 21, 2025
PubMed

Insights

Erdheim-Chester disease (ECD) is a rare condition causing histiocyte buildup. Novel targeted therapies show promise for improving outcomes in this challenging disorder.

Area of Science:

  • Rare diseases
  • Histiocytosis
  • Oncology

Background:

  • Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by excessive histiocyte accumulation.
  • It affects multiple organs, leading to significant morbidity including bone, cardiovascular, and neurological complications.
  • Limited efficacy and side effects of traditional treatments necessitate novel therapeutic approaches.

Purpose of the Study:

  • To provide a comprehensive review of Erdheim-Chester disease.
  • To discuss clinical manifestations, radiographic features, and current treatment strategies.
  • To highlight recent advances and emerging therapies for ECD.

Main Methods:

  • Literature review of Erdheim-Chester disease.
  • Analysis of clinical manifestations and radiographic findings.
  • Evaluation of traditional and novel treatment strategies, including targeted therapies.

Main Results:

  • ECD presents with heterogeneous clinical manifestations and radiographic features.
  • BRAF V600E mutation plays a key role in ECD pathogenesis.
  • Targeted therapies (BRAF, MEK, mTOR inhibitors) and immunotherapies show promise.

Conclusions:

  • Understanding ECD pathogenesis, particularly the BRAF V600E mutation, is crucial for treatment development.
  • Novel targeted therapies offer improved outcomes for Erdheim-Chester disease patients.
  • Further research and clinical studies are essential to optimize ECD management.

Keywords:
BRAF inhibitorsClinical studiesECDErdheim-Chester diseaseMEK inhibitorsMTOR inhibitorsRadiographic featuresTargeted therapiesTreatment strategies

More Related Videos

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

6.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

440

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
109
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
70